CRA was retained in an international arbitration between two Japanese affiliates of multinational pharmaceutical companies. The dispute concerned Respondent’s performance under a co-promotion agreement. CRA’s team of life sciences consultants assessed indicators of commercially reasonable efforts using various industry data sources. The CRA team also quantified Claimant’s loss resulting from the alleged inadequate performance under the agreement, and responded to Respondent’s expert regarding damages alleged by Respondent.
Q&A with Greg Bell in Power Players: International Arbitration 2023 – Exceptional experts
As scientific advances continue to generate new commercial opportunities, Gregory Bell expects an increase in intercompany collaborations. However, that may...